Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.49
- Piotroski Score 6.00
- Grade Outperform
- Symbol (DXCM)
- Company DexCom, Inc.
- Price $68.93
- Changes Percentage (0.47%)
- Change $0.32
- Day Low $67.70
- Day High $68.98
- Year High $142.00
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $95.00
- High Stock Price Target $146.00
- Low Stock Price Target $28.13
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.55
- Trailing P/E Ratio 74.7
- Forward P/E Ratio 74.7
- P/E Growth 74.7
- Net Income $541.50 M
Income Statement
Quarterly
Annual
Latest News of DXCM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
DexCom (DXCM) Fell Due to an Uncharacteristic Earnings Miss
Aristotle Atlantic Partners reported its "Focus Growth Strategy" Q3 2024 performance, returning 2.84% gross of fees. DexCom, Inc. faced challenges but remains promising. The company's stock price clos...
By Yahoo! Finance | 6 days ago -
Is DexCom, Inc. (NASDAQ:DXCM) The Worst Performing S&P 500 Stock In 2024?
The article discusses the market's recent winning streaks and DexCom, Inc.'s performance in 2024. It highlights a shift towards value investments over tech due to election and geopolitical uncertainti...
By Yahoo! Finance | 1 week ago -
Multiple Headwinds Dragged DexCom (DXCM) in Q3
Baron Funds' Q3 2024 letter reports US equities rising, with their Baron Asset Fund outperforming. DexCom, Inc. (NASDAQ:DXCM) faced challenges leading to Baron Funds exiting their investment....
By Yahoo! Finance | 1 week ago
